Class III Antiarrhythmic Drugs: Simple versus Complex Molecules for Controlling Cardiac Arrhythmias

Singh BN , Vaughan Williams EM. A third class of antiarrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ1999 and AH 3474. Br J Pharmacol 39:675, 1970

Singh BN , Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, on cardiac muscle. Br J Pharmacol 39:657, 1970

Charlier R. , Deltour G. , Baudine A. et al. Pharmacology of amiodarone, an antianginal drug with a new biological profile. Arzneimittelforschung 18:1408, 1968

Singh BN , Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 87:367, 1974

Singh BN , Vaughan Williams EM. Effects of altering potassium concentration on the action lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res 29:286, 1971

Singh BN The coming of age of class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol 78(suppl 4A):17, 1996

Mason JW and Esvem Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias . N Engl J Med 329:452, 1993

The CASCADE Investigators. The Cascade Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. Am J Cardiol 72:280, 1993

Wever EF , Hauer Rnw , Van Capelle FJL , et al. Randomized study of implantable defibrillator as first-choice versus conventional strategy in post-infarct sudden death survivors. Circulation 91:2195, 1995

Singh BN , Ahmed R. Class III antiarrhythmic drugs. Current Opin Cardiol 19:12, 1994

Sicouri S. , Moro S. , Elizari MV d-Sotalol induces marked action potential prolongation and early afterdepolarizations in M but not epicardial or endocardial cells of the canine ventricle. J Cardiovasc Pharmacol Therapeut 2:27, 1997

Nakaya Y. , Martin DK , Campbell TJ The novel class III antiarrhythmic agent MS-551 blocks the cardiac inward rectifier with greater potency than sotalol or E4031: possible relevance to reverse use dependence. J Cardiovasc Pharmacol Therapeut 2:39, 1997

Antzelevitch C. Editorial comment: the M cell. J Cardiovasc Pharmacol Therapeut 2:73, 1997

Lukas A. Electrophysiology of myocardial cells in the epicardial, myocardial and endocardial layers of the ventricle. J Cardiovasc Pharmacol Therapeut 2:61, 1997

Singh BN Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact. Eur Heart J 14:14, 1993

Waldo AL , Camm AJ , de Ruyter H. , et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 343:7, 1996

Roden DM Ibutilide and the treatment of atrial arrhythmias. Circulation 94:1499, 1996

Julian DG , Jackson FS , Prescott RJ , Szekely P. Control trial of sotalol for one year after myocardial infarction. Lancet 1:1142, 1982

Groh WJ , Gibson KJ , McAulty JH , Maylie JG β-adrenergic blocking property of dl-sotalol maintains class III efficacy in guinea pig ventricular muscle after isoproterenol. Circulation 68:77, 1995

Polster P. , Broekhuysen J. The adrenergic antagonism of amiodarone. Biochem Pharmacol 25:131, 1976

Sicouri S. , Moro S. , Siri LN et al. Chronic amiodarone delays ventricular repolarization and reduces transmural dispersion of repolarization in the canine heart. PACE 1911:638(Abstract), 1996

Singh BN Amiodarone and homogeneity of ventricular repolarization and refractoriness . J Cardiovasc Pharmacol Therapeut 1:265, 1996